After yet another FDA delay regarding Vascepa's NCE status, Amarin (AMRN -4.94%) investors may have something to celebrate today: The company stayed true to its reported timeline and has launched its lipid-lowering drug. While this launch does signify progress at the company, it will go head to head with Lovaza, a drug marketed by pharma giant GlaxoSmithKline (GSK -0.83%). In this video, our health care analyst Max Macaluso discusses whether this is news investors should welcome -- and what they should be wary of.
Free Article
The Day Amarin Investors Have Waited For
By Max Macaluso
–
Jan 24, 2013 at 4:05PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$356M
Today's Change
(-4.94%) -$0.05
Current Price
$0.87
Price as of April 18, 2024, 4:00 p.m. ET
It's finally here... but it's not NCE.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.